Gene therapy cures 10 patients with rare immune disease: study
Ten infants have been cured of a rare genetic disease called Artemis-deficient severe combined immunodeficiency (ART-SCID), according to research by scientists in the US and Canada.
The study was published by M.J. Cowan et al. in The New England Journal of Medicine.
ART-SCID affects approximately one in 65,000 newborns and causes life-threatening problems with the immune system. It’s caused by faulty copies of a gene that codes for a DNA repair enzyme called Artemis, which is required for the production of functioning immune cells.
The infants were conditioned with an intravenous low-dose of the cancer drug Busulfan before the team injected them with gene-corrected cells. These were obtained through bone marrow harvest and transduced with a lentiviral vector.
No unexpected adverse events were reported in safety assessments up to 42 days after transfusion.
Busulfan toxicity manifested as transient cytopenias: Anemia, Thrombocytopenia and Neutropenia. Four patients developed Autoimmune Hemolytic Anemia between 4 and 11 months after the transfusion, but this was resolved with reconstitution of T-cell immunity.
On follow-up, all the infants had genetically corrected and functional immune cells.
AdPha releases strategic plan towards 'pharmacy in 2030'
Advanced Pharmacy Australia has released Yindyamarra 2030 — its forward vision for pharmacy...
Victoria to roll out new ambulance and emergency care standards
The new Standards for Safe and Timely Ambulance and Emergency Care for Victorians will be...
Medical student convicted for holding out as a surgeon
A medical student who held himself out as a medical practitioner to three women — two he...
